scholarly journals Improvement of atopic dermatitis and alopecia universalis with dupilumab: a case report

2021 ◽  
Author(s):  
Lama Alotaibi ◽  
Abdulrahman Alfawzan ◽  
Raghad Alharthi ◽  
Afaf Al sheikh
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
Alopecia Areata ◽  
Alopecia Universalis ◽  
Receptor Alpha ◽  
Alpha Antagonist

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that showed significant improvement of atopic dermatitis (AD). Many reports have shown significant resolution of alopecia areata, alopecia universalis, and alopecia totalis after dupilumab treatment for AD. We present one of the few reported cases that showed improvement of underlying alopecia universalis treated with dupilumab.

scholarly journals Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report

2019 ◽  
Vol 99 (7) ◽  
pp. 675-676 ◽  
Author(s):  
H Uchida ◽  
M Kamata ◽  
A Watanabe ◽  
A Agematsu ◽  
M Nagata ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
Alopecia Areata

scholarly journals Effective treatment of alopecia universalis with oral tofacitinib: A case report

2021 ◽  
Vol 12 (1) ◽  
pp. 33-36
Author(s):  
Lenah Shaikh ◽  
Amnah Almulhim ◽  
Manal Al Rabai ◽  
Yasir Shaikh
Keyword(s):  
Case Report ◽  
Autoimmune Disease ◽  
Effective Treatment ◽  
Hair Loss ◽  
Alopecia Areata ◽  
The Body ◽  
Entire Body ◽  
Alopecia Universalis ◽  
One Year ◽  
Persistent Response

Alopecia areata is a common autoimmune disease presenting itself with patches of hair loss on the scalp, eyebrows, eyelashes, or any part of the body. It may manifest itself as a single patch, involving the entire scalp (alopecia totalis), or affecting the entire body, thus the name alopecia universalis. Multiple lines of treatment may be employed, but no single most effective treatment exists, especially if the condition is generalized and, thus, becomes more difficult to treat. Herein, we report a case of alopecia universalis treated with oral tofacitinib with an excellent and persistent response one year after.

Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report

2021 ◽  
Author(s):  
Hideaki Uchida ◽  
Masahiro Kamata ◽  
Mayumi Nagata ◽  
Saki Fukaya ◽  
Kotaro Hayashi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
Alopecia Areata

scholarly journals Alopecia Universalis Associated with Hyperthyroidism Treated with Azathioprine and Hydroxychloroquine: A Case Report

2021 ◽  
Vol 59 (241) ◽  
pp. 935-937
Author(s):  
Vikash Paudel ◽  
Deepa Chudal ◽  
Manish Bhakta Pradhan ◽  
Rupa Thakur ◽  
Buddhi Raj Pandey
Keyword(s):  
Case Report ◽  
Hair Loss ◽  
Alopecia Areata ◽  
Treatment Modalities ◽  
Alopecia Universalis ◽  
Multiple Treatment ◽  
Gradual Onset ◽  
Fourth Decade

Alopecia universalis is an uncommon form of alopecia areata involving hair loss over the entire scalp and body. This condition is difficult to treat and sustain the growth of hair for longer duration. We report a case of alopecia universalis associated with severe hyperthyroidism. A lady in her fourth decade presented to us with gradual onset of alopecia universalis, who later found to have hyperthyroidism which was refractory to multiple treatment modalities. She was treated successfully with azathioprine and hydroxychloroquine. Alopecia universalis with less response to oral steroidtherapy was successfully managed with azathioprine with hydroxychloroquine.

Wenn die Haare einen verlassen und nie mehr wiederkehren

Praxis ◽  
2003 ◽  
Vol 92 (19) ◽  
pp. 912-914
Author(s):  
von Mühlenen ◽  
Schaub
Keyword(s):  
Alopecia Areata ◽  
Alopecia Universalis

Ein 23-järiger Mann leidet seit Kindheit an Haarverlust mit einem fast kompletten Fehlen der Kopfhaare seit seinem sechsten Altersjahr. In den letzten Monaten war es zu einem Fortschreiten der Erkrankung mit Entwicklung einer Alopecia universalis gekommen. Wir diskutieren die Pathogenese, Differentialdiagnose und Therapie der Alopecia areata.

Remission of Alopecia Universalis after 1 Year of Treatment with Dupilumab in a Patient with Severe Atopic Dermatitis

2021 ◽  
pp. 1-4
Author(s):  
Maurizio Romagnuolo ◽  
Mauro Barbareschi ◽  
Simona Tavecchio ◽  
Luisa Angileri ◽  
Silvia Mariel Ferrucci
Keyword(s):  
Atopic Dermatitis ◽  
Skin Disorder ◽  
Human Monoclonal Antibody ◽  
Severe Atopic Dermatitis ◽  
T Helper ◽  
T Helper 1 ◽  
Th2 Response ◽  
Alopecia Universalis ◽  
T Helper 2 ◽  
Relapsing Remitting

Alopecia areata (AA), an autoimmune disease with a relapsing-remitting course, represents the second cause of non­scarring alopecia worldwide and is associated with several comorbidities, notably atopic dermatitis (AD). In particular, AD is related to its more severe forms alopecia totalis (AT) and alopecia universalis (AU) [Nat Rev Dis Primers. 2017;3:17011]. Considering that AA has been classified as T helper 1-driven disease, whereas AD is the prototypical T helper 2 (Th2)-driven skin disorder, recent studies suggest that these forms may underlie a different chemokine expression resulting in a Th2 skewing as a key pathomechanism that could explain this association [JAMA Dermatol. 2015 May;151(5):522–8]. Several reports showed that dupilumab, a fully human monoclonal antibody targeting the interleukin 4α receptor and thus downregulating Th2 response, led to an improvement of AA associated with AD; most of these patients were females with AT or AU, early-onset AD, and atopic comorbidities [Exp Dermatol. 2020 Aug;29(8):726–32]. We report here a case to further support this hypothesis.

scholarly journals Alopecia areata-like and cutaneous psoriasis after dupilumab use for the treatment of atopic dermatitis

2021 ◽  
Author(s):  
Viviane Maria Maiolini ◽  
Nathalie Andrade Sousa ◽  
Paula Figueiredo de Marsillac ◽  
Aline Lopes Bressan
Keyword(s):  
Atopic Dermatitis ◽  
Alopecia Areata
Sign in / Sign up

Export Citation Format

Share Document